Châtillon, France, September 3, 2026

DBV Technologies to Participate in Upcoming September Investor Conferences

DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September:

2026 Cantor Global Healthcare Conference – September 9, 2026

Format:         Fireside Chat

Time:            1:00pm ET

Location:       New York, NY

Citi’s 2026 Biopharma Back to School Conference – September 10, 2026

Format: 1 on 1 Meetings

Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference – September 15, 2026

Format:         Fireside Chat

Time:            3:00pm ET

Location:      New York, NY

Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.

About DBV Technologies

DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact

Jonathan Neely

DBV Technologies

Jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

DBV Technologies

Brett.whelan@dbv-technologies.com

Attachment

PDF Version